Amneal to Acquire Kashiv BioSciences for $750M, Boosting Biosimilar Ambitions
Event summary
- Amneal Pharmaceuticals to acquire Kashiv BioSciences for $750M upfront, with up to $350M in potential milestone payments.
- Deal positions Amneal to capitalize on a $300B+ global biologics loss-of-exclusivity opportunity over the next decade.
- Amneal reports Q1 2026 revenue of $723M, up 4% YoY, with Specialty revenue growing 23%.
- Transaction expected to close in the second half of 2026, subject to shareholder and regulatory approvals.
- Amneal raises FY2026 guidance, projecting $3.05B–$3.15B in revenue and $740M–$770M in adjusted EBITDA.
The big picture
Amneal’s acquisition of Kashiv BioSciences solidifies its position as a global biosimilar leader, capitalizing on the impending wave of biologics losing exclusivity. The deal aligns with broader industry trends toward cost-effective, high-quality biologic medicines, as biosimilar adoption accelerates across physicians, patients, and payers. With strong Q1 2026 financial results and raised FY2026 guidance, Amneal is positioning itself for sustained growth and long-term value creation in the biosimilar space.
What we're watching
- Integration Challenges
- How Amneal will merge Kashiv’s R&D and manufacturing capabilities with its commercial scale to create a fully integrated biosimilar platform.
- Regulatory Approvals
- Whether the transaction will receive timely approvals from Amneal shareholders and regulators, given the expected close in the second half of 2026.
- Market Positioning
- The pace at which Amneal can establish leadership in the biosimilar market ahead of the projected $300B+ biologics loss-of-exclusivity wave.
Related topics